文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

低剂量甲泼尼龙治疗重症社区获得性肺炎危重患者

Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia.
PubMed 文献 · Intensive Care Med · 2022-05-13
一句话结论重症社区获得性肺炎患者接受20天低剂量甲泼尼龙治疗未显著降低60天死亡率(16% vs 18%,校正OR 0.90,95%CI 0.57-1.40),且未增加并发症。

该双盲、随机、安慰剂对照试验纳入成人重症社区获得性肺炎(CAP)需ICU入住患者,于就诊后72-96小时内随机分组,甲泼尼龙组给予静脉40 mg负荷量后40 mg/天至第7天,并在20天疗程内逐步减量。2012年1月至2016年4月共从42个退伍军人医疗中心随机586例,因招募缓慢未达1420例目标样本量,584例纳入分析。主要终点60天全因死亡率两组无显著差异(16% vs 18%;校正OR 0.90,95%CI 0.57-1.40),次要结局及并发症亦无显著差异。结论:延长低剂量甲泼尼龙治疗未显著降低60天死亡率,且未增加并发症。

要点

  • 重症CAP需ICU患者中,甲泼尼龙组60天死亡率16% vs 安慰剂组18%,校正OR 0.90(95%CI 0.57-1.40),无显著差异。
  • 甲泼尼龙方案:静脉40 mg负荷量,随后40 mg/天至第7天,20天疗程内逐步减量。
  • 治疗未增加并发症,次要结局(至1年随访的发病率与死亡率)无显著差异。
  • 研究因招募缓慢未达目标样本量(实际586例 vs 目标1420例),584例纳入分析。

适用人群与场景

  • 成人重症社区获得性肺炎(CAP)需入住ICU的患者。
  • 于医院就诊后72-96小时内入组。

处置流程与药物剂量

  • 甲泼尼龙组:静脉40 mg负荷量,随后40 mg/天至第7天,20天疗程内逐步减量。
  • 安慰剂对照组。

研究设计与关键结果

  • 研究类型:双盲、随机、安慰剂对照临床试验;42个退伍军人医疗中心;2012年1月至2016年4月随机586例,584例纳入分析;因招募缓慢未达1420例目标样本量。
  • 主要终点:60天全因死亡率甲泼尼龙组16% vs 安慰剂组18%,校正OR 0.90(95%CI 0.57-1.40),无显著差异。
  • 次要终点:至1年随访的发病率与死亡率无显著差异;并发症无显著差异。

证据类型、等级与局限

  • 证据类型:双盲、随机、安慰剂对照临床试验。
  • 局限:因招募缓慢未达目标样本量(实际586例 vs 目标1420例)。

对床旁实践的改变

  • 在重症CAP需ICU患者中,延长低剂量甲泼尼龙治疗未显著降低60天死亡率,且未增加并发症。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Severe community-acquired pneumonia (CAP) requiring intensive care unit admission is associated with significant acute and long-term morbidity and mortality. We hypothesized that downregulation of systemic and pulmonary inflammation with prolonged low-dose methylprednisolone treatment would accelerate pneumonia resolution and improve clinical outcomes.

METHODS: This double-blind, randomized, placebo-controlled clinical trial recruited adult patients within 72-96 h of hospital presentation. Patients were randomized in 1:1 ratio; an intravenous 40 mg loading bolus was followed by 40 mg/day through day 7 and progressive tapering during the 20-day treatment course. Randomization was stratified by site and need for mechanical ventilation (MV) at the time of randomization. Outcomes included a primary endpoint of 60-day all-cause mortality and secondary endpoints of morbidity and mortality up to 1 year of follow-up.

RESULTS: Between January 2012 and April 2016, 586 patients from 42 Veterans Affairs Medical Centers were randomized, short of the 1420 target sample size because of low recruitment. 584 patients were included in the analysis. There was no significant difference in 60-day mortality between the methylprednisolone and placebo arms (16% vs. 18%; adjusted odds ratio 0.90, 95% CI 0.57-1.40). There were no significant differences in secondary outcomes or complications.

CONCLUSIONS: In patients with severe CAP, prolonged low-dose methylprednisolone treatment did not significantly reduce 60-day mortality. Treatment was not associated with increased complications.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Meduri GU, Shih MC, Bridges L, et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022. PMID: 35723686. doi:10.1007/s00134-022-06684-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。